Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 21, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 565,000 Ordinary shares of 25 pence each.
- Purchase Date: February 21, 2012.
- Price Range: Highest price paid was 1,420.0 pence per share; lowest price paid was 1,401.0 pence per share.
- Treasury Holdings (Settled): 504,192,927 shares (9.08% of total issued share capital).
- Treasury Holdings (Including Unsettled): 505,817,927 shares (10.02% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,050,342,083 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 565,000 shares, which were intended to be held in Treasury. This transaction increased the percentage of total voting rights held in Treasury to 10.02% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (504,192,927 settled) against the company's latest capitalization table.
- Confirm the impact of the 10.02% Treasury holding on total voting rights calculations.
- Check the remaining authorization for share repurchases under the mandate granted on May 5, 2011.
- Review the settlement status of the 565,000 shares purchased on February 21, 2012.